Welcome to The Body PRO Newsletter, a bi-weekly review of the latest breaking news and research in HIV medicine, aimed specifically at informing health care professionals.

March 21, 2012

In This Newsletter:


Paul Sax, M.D.CROI 2012 Really Rapid Review
Paul Sax, M.D., shares this quick and completely subjective (yet deeply informative) list of highlights from the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012), which took place earlier this month in Seattle, Wash.

Ben Young, M.D., Ph.D.State of ART at CROI: New Concepts and New Integrase Inhibitors
"HIV drugs in development may no longer command a lion's share of CROI as they once did, but sessions devoted to new antiretrovirals and promising paths for HIV treatment are still filled to bursting," reports Ben Young, M.D., Ph.D.

ard Ellion, M.D.HIV Treatment Update From CROI 2012 (Video)
IFARA brings you this interview with Cal Cohen, M.D., and Richard Ellion, M.D., on noteworthy CROI presentations highlighting new research on HIV antiretrovirals in development, the treatment of HIV/HCV coinfection, and metabolic complications and malignancies in people with HIV.

Nelson VergelSome Patients Develop Spontaneous Control of HIV After Short-Term HAART During Acute Infection
Case reports suggest that HAART initiated immediately after infection and continued for only one to two years may allow a small number of patients to maintain immunologic control of HIV infection for years after discontinuing treatment.

Breakthroughs in HIV/HCV-Coinfection Treatment Shine at CROI 2012
"Hepatitis C treatment for with HIV is the Wild West of drug discovery," writes Ben Young, M.D., Ph.D., from CROI 2012. "Unless one closely follows the major research conferences, it's easy for practicing clinicians to be bewildered and run over by the veritable stampede of clinical studies and findings."

More Headlines on HIV Care and Antiretroviral Therapy:

  Back to Top


HIV newsIndia Issues "Compulsory License" Legalizing Generic Drugs; Could Have Implications for HIV Treatment Access
India's Patent Office has set an important new precedent in generic drug access: This week, it said that a local generic drug maker could legally make and sell a generic form of a patented anti-cancer medication. The move could ultimately have a huge impact on generic HIV medication access as well.

Kellee TerrellWhen Will Male HIV/AIDS Leaders Make Women and Girls a Priority?
"We are drowning in a culture that seriously devalues women, and unfortunately, the HIV/AIDS movement is part of that same culture," our news editor Kellee Terrell writes. "I challenge male leaders to stop with the sappy pseudo-empowering rhetoric about how women and girls can overcome this epidemic and how our voices really do matter."

Aless PiperAless Piper: Flaming Red's Social Media Toolkit
"I truly believe that there is absolutely no reason why someone who wants to be involved, should not be involved in some way," writes HIV/AIDS activist Aless Piper. "Likewise, I believe that there is absolutely no reason for [HIV/AIDS organizations] to not be present and accounted for on social media."

More News & Views Headlines:

  Back to Top


PrEP Grabs Spotlight at CROI 2012; Focus on Importance of Adherence
Pre-exposure prophylaxis (PrEP) remains a promising avenue for HIV prevention, but ensuring adequate adherence is proving to be a particular challenge. Researchers with the FEM-PrEP study are among several to present data highlighting this challenge.

Dennis Burton, Ph.D.Update on HIV Vaccines and Broadly Neutralizing Antibodies (Video)
In this interview from IFARA, Dennis Burton, Ph.D., offers his sense of where we are today and where we're going in work around broadly neutralizing antibodies and HIV vaccines.

More Headlines on HIV/STD Transmission:

  Back to Top


Justin B. Terry-SmithJoin the "Write a Letter to HIV" Campaign
"I've decided to write a letter expressing my feelings about HIV and I'm asking YOU to join me," blogger Justin B. Terry-Smith writes. "If you're infected or affected by HIV, I'm asking that you write a letter and then videotape yourself reading the letter aloud. It helps sometimes to get your feelings out."

Jamar RogersJamar Rogers: The Story Behind the Voice
On Feb. 6, Jamar Rogers shared his HIV-positive status with millions of viewers as a prospective contestant on NBC's performance competition show The Voice. In this inspiring interview with POZIAM Radio, Jamar opens up about everything from his HIV diagnosis to being part of the show's cast.

Khafre AbifKhafre Abif: The Power of Words
"Cornbread, Fish and Collard Greens: Prayers, Poems & Affirmation for People Living with HIV/AIDS has received submissions from Africa, America, Europe and South America. ... Share the campaign with your family, friends and your social network. All the tools are there."

B. OstenB. Osten: The Day I Was Diagnosed With HIV
"Like many of my generation, the answer to HIV and AIDS was 'Don't ask. Don't tell.' I never thought the reality of it would hit so close to home," recalls blogger B. Osten. "Reflecting back, the telltale signs of the disease were in plain sight. I guess I just refused to see it."

  Back to Top


Also Worth Noting

2011: The Year in Review

•  Top HIV/AIDS-Related Clinical Developments of 2011

David Wohl, M.D., takes an in-depth look at the past year's most critical HIV-related studies, and explains how each may change the manner in which we practice HIV prevention or treatment in 2012 and beyond.

HIV Management Today

In HIV Management Today, an informative online series from TheBodyPRO.com, we consult with some of the top clinical minds in HIV on some of the most important issues in HIV/AIDS clinical management.

•  Assessing and Acting on Cardiovascular Disease Risk in HIV-Infected Patients, featuring Marshall Glesby, M.D., Ph.D., and Jens Lundgren, M.D.

•  A Closer Look at Tesamorelin (Egrifta), a Treatment for HIV-Associated Lipohypertrophy, featuring Daniel Berger, M.D.

•  Clinical Management of the HIV-Infected Woman, featuring Kimberly Smith, M.D., M.P.H., and Valerie Stone, M.D., M.P.H.